Cours Approfondi de Chimiothérapie Infectieuse et Vaccinologie

A propos d'un cas d'endocardite

Pr France Roblot
Faculté de Médecine et de pharmacie de Poitiers
CHU de Poitiers
INSERM U1070

Déclaration liens d'intérêts 2020 - 2025

- Intervenante au titre d'orateur

GSK, MSD, Menarini, Moderna, Pfizer, Sanofi

- Participation à des groupes de travail

Gilead, GSK, Mundipharma

- Invitation congrès/journées scientifiques

Eumedica, Pfizer, Sanofi

- Vice-présidente de la SPILF (2024)
- Conseil National Professionnel des maladies infectieuses et tropicales
- Cs MIME du HCSP

Cas clinique (1)

- Femme de 70 ans, Guyane
- ATCD : HTA, abcès de cornée à pneumocoque post cataracte (2020)
- Admission 08/2023 : fièvre depuis 48H + dyspnée + épigastralgies + vomissement
- Ex clinique initial : 40,6°C, FR 18/mn, FC 99/mn, souffle systolique mitral (?), pas de foyer de crépitants, douleur HCD
- Sat O2 98% AA

Cas clinique (1)

- Biologie :
  - NFS leucocytes 16 000/mm3 (85% PNN); plaquettes 168 000 /mm3, Hb 12,6 g /dl
  - ASAT 143 UI/l (N<35), ALAT 208 UI/l, K+2,8 mmol/l, CRP 105 mg/l, clairance créat 97 ml/mn (MDRD)
  - 4 hémocultures positives à *S. pneumoniae*

Quel bilan morphologique demandez-vous ?

- Rx thoracique ?
- TDM thoracique ?
- ETT ?
- TDM abdominale ?
- Autre ?


100 mm

Indication ETT ?

- Score HANDOC : streptocoques non β-hémolytiques
  - ETT/ETO si score ≥ 3
  - Sensibilité 100% et VPN 100%
  - Validation extrinsèque peu robuste
    - 1 étude de la même équipe
    - 1 autre étude sur petit effectif

Sunnerhagen T, HANDOC: A Handy Score to Determine the Need for Echocardiography in Non-ß-Hemolytic Streptococcal Bacteremia.

Variable
Heart murmur or valvular disease (H) 1 point for the presence of a valvular disease or prosthesis or the finding of a heart murmur.
Aetiology (A) 1 point if the species is in the *S. bovis*, *S. sanguinis*, or *S. mutans* group. Subtract 1 point if in *S. anginosus* group. Other streptococcal groups neither give nor subtract points.
Number of cultures (N) 1 point if the number of blood cultures containing NBHS is 2 or more.
Duration of symptoms (D) 1 point if the duration of symptoms is 7 days or more
Only 1 species (O) 1 point if there is only 1 bacterial species in the blood cultures
Community acquired (C) 1 point if the infection is community acquired

Indication ETT ?

(Bouza, E et al Clin Infect Dis 20215)

- **NOVA score**

Table 4. Score for Assessing the Risk of Infective Endocarditis in Patients With Enterococcal Bloodstream Infections

ETT si score ≥ 4

Variable	Points	Odds Ratio (95% Confidence Interval)
Number of positive blood cultures (N)	5	9.9 (2.2–40.6)
Unknown origin of bacteremia (O)	4	7.7 (2.5–23.8)
Prior valve disease (V)	2	3.7 (1.6–8.7)
Auscultation of a heart murmur (A)	1	1.8 (.77–4.3)
Total	12	

(Berge A et al, Infection 2019)

- **DENOVA score**

Table 2 Variables of the DENOVA score, each giving 1 point, and their association with IE in multivariate analyses

ETT si score ≥ 3

	Odds ratio (95% CI)	*p* value
Duration of symptoms ≥ 7 days	9.7 (3.6–26)	<0.001
Embolization	50 (6.2–400)	<0.001
Number of positive cultures ≥ 2	6.8 (1.5–32)	0.01
Origin of infection unknown	7.3 (2.0–26)	0.003
Valve disease	1.7 (0.57–4.9)	0.35
Auscultation of murmur	13 (4.7–36)	<0.001

Table 2
Performance of NOVA and DENOVA scores.

Score	Cohort	Se%	Sp%	PPV%	NPV%	LR+	LR-
DENOVA	Cohort A (n = 412)	94.64	84.27	48.62	99.01	6.02	0.06
	Cohort A+B (n = 635)	95.34	84.27	-	-	6.06	0.06
	Cohort A+B with echocardiography (n = 386)	95.32	59.26	-	-	2.34	0.08
NOVA	Cohort A (n = 412)	98.21	55.34	25.70	99.49	2.20	0.03
	Cohort A+B (n = 635)	98.92	55.34	-	-	2.21	0.02
	Cohort A+B with echocardiography (n = 386)	98.92	28.70	-	-	1.39	0.04

Se: Sensitivity. Sp: Specificity. PPV: Predictive Positive Value. NPV: Negative Predictive Value. LR: Likelihood Ratio.

(Danneels P et al J Infect 2023)

Bactériémie à *S. pneumoniae* et ETT ?
Risque endocardite / espèce

- Cohorte bactériémies à Streptocoques
- Danemark, 2008-2017
- 6506 BSI
- *S. pneumoniae* 1.2% (0.8–1.6)
  + faible risque EI



Figure 3. Prevalence of infective endocarditis in bloodstream infections with different streptococcal species.
The figure shows the prevalence of infective endocarditis (IE) in bloodstream infections (BSIs) with different streptococcal species. The horizontal axis (disproportionate) shows number of BSI cases and the vertical axis the prevalence of IE. The size of each circle represents the numeric number of IE cases according to the specific species. The area of each circle is proportional with number of IE cases with a range from 4 to 80 cases. The color scale from green to red highlights the increasing prevalence of IE.

(Chamat-Hedemand S et al, Circulation 2020)

Bactériémie à *S. pneumoniae* et ETT ? Risque endocardite / espèce

- Méta analyse / 30 ans, bactériémies à Streptocoques + endocardite
- S. mutans: 47% (95% CI 38–56%), S. cristatus: 41% (95% CI 21–62%), S. gordonii: 37% (95% CI 30–44%), S. sanguinis: 33% (95% CI 28–39%), and S. gallolyticus: 31% (95% CI 27–36%)
- *S. pneumoniae*



Fig. 2: Infective endocarditis prevalence of streptococcal species vs. proportion of streptococcal species bacteraemia. Coloured by increasing endocarditis risk, green (low < 10%) to red (high > 35%). Circles are proportionate to the total number of endocarditis cases. The vertical lines represent the 95% confidence intervals around the proportion of bacteraemias with endocarditis.

(Deas G et al, www.thelancet.com 2025)

Quel bilan morphologique demandez-vous ?

- Rx thoracique
- TDM thoracique ?
- ETT ?
- TDM abdominale ?
- Autre

Cas clinique (2)

- ETT à J4 :

- Hypertrophie septale globale, FEVG préservée (77 %)
- fuite mitrale modérée, par dysfonction du feuillet postérieur;
- **image mobile suspecte de végétation** dans le contexte, appendue à la face auriculaire de l'anneau mitral postérieur (12 X 2.5 mm)
- flux mitral de type 2
- OG dilatée (44 ml/m^2)

Endocardite à pneumocoque ?

- Possible car fréquence = 10% des IE sur valve native ?
- Peu probable car pas de FRD d'infection invasive à pneumocoque ?
- Peu probable car pas de valve prothétique ?
- Peu probable car pas de foyer de pneumonie ?

Endocardite à pneumocoque ?

- < 2% des EI (Selton-Sury C et al, CID 2012)
- 0,86% cohorte Espagne (de Egea V et al, Medicine 2015)
- 0,47% cohorte Brésil (Mamani RF et al, Braz J Infect Dis 2024)
- 1.2% EI/bactériémies à pneumocoques, Danemark (0.8-1.6)

(Chamat-Hedemand S et al, Circulation 2020)

- 0.3% des infections invasives à pneumocoque, Canada

(Marrie TJ et al, Eur J Clin Microbiol Infect Dis 2018)

Table 3. Distribution of Causative Microorganisms in Patients With Infective Endocarditis

Microorganisms	No. (%) of Patients (n = 497)	
Streptococcaceae	240	(48.3)
Streptococci	180	(36.2)
Oral streptococci[a]	93	(18.7)
Group D streptococci[b]	62	(12.5)
Pyogenic streptococci	25	(5.0)
Enterococci	52	(10.5)
Other Streptococcaceae[c]	8	(1.6)
Staphylococcaceae	180	(36.2)
Staphylococcus aureus	132	(26.6)
Coagulase-negative staphylococci	48	(9.7)
Other microorganisms[d]	42	(8.5)
HACEK group	6	…
Enterobacteriaceae	4	…
Propionibacterium acnes	4	…
Pseudomonas aeruginosa	3	…
Lactobacillus species	2	…
Corynebacterium species	2	…
Coxiella burnetii	2	…
Bartonella quintana	1	…
Tropheryma whipplei	1	…
Candida species	6	…
Miscellaneous[e]	11	…
≥2 Microorganisms[f]	9	(1.8)
No microorganism identified	26	(5.2)

Clinique

Demographic and clinical characteristics of 50 patients with definite pneumococcal endocarditis.

Characteristics[a]	N = 50
Baseline	
Age at diagnosis (years), mean ± SD	60 ± 14
Male gender	38 (76)
Clinical and biological manifestations	
Fever	
Vascular phenomena[b]	
Immunological phenomena[c]	
Pneumonia	
Meningitis	
Arthritis	
Ocular infection	
Other infectious localizations[d]	
Blood cultures positive for *S. pneumoniae*	
Positive histopathological examination and/or c	
Affected valve	
Native	
Prosthesis	
Mitral	
Aortic	
Tricuspid	8
Transthoracic echocardiographic findings	
TTE positive for IE	50 (100)
Vegetations	44 (88)
Abscess	14 (30)
Valve regurgitation	38 (79)
Dehiscence of prosthesis	0

Âge
Localisations associées +++
Pneumonie
Méningite
Arthrite

Valve native (93,7%), aorte (53,2%)

TABLE 2. Demographic and Clinical Characteristics of 111 Patients With *Streptococcus pneumoniae* Endocarditis

Characteristics	Total Cohort N = 111 (%)	Spanish Cohort n = 24	Literature Review n = 87
Age (median, IQR)	51 (26–63)	57 (50–69)	47 (15–61)
Sex			
Male	71 (64)	18 (75)	53 (60.9)
		0 (0)	11 (12.9)
		6 (27.3)	2 (2.4)
		1 (4.2)	5 (6.4)
		21 (87.5)	58/61 (95,1)
		17 (77.3)	44/55 (80.0)
		9 (37.5)	42/84 (50.0)
		7 (29.2)	38/84 (45.2)
		3 (12.5)	26/84 (31.0)
		0 (0)	5/62 (8.1)
		3 (13)	0 (0)
		20 (83.3)	84 (96.6)
		4 (16.7)	3 (3.4)
Aortic	59 (53.2)	14 (58.3)	45 (51.7)
Mitral	45 (40.5)	10 (41.7)	35 (40.2)
Tricuspid	14 (12.6)	3 (12.5)	11 (12.6)
More than 1 valve affected	15 (13.5)	3 (12.5)	12 (13.8)

(Périer A et al, Int J Cardiol 2019
de Egea V et al, Medicine 2015)

Syndrome d'Austrian

- Méningite + pneumonie + endocardite
- 71 cas, âge moyen 56,5 ans, sex ratio 2,4/1
- Alcool 41%
- Trouble de la cs (69%), fièvre (65%)
- Valve aortique (56%)
- Chirurgie valvulaire (65%)
- Admission USI (50, 70%) + VM (43, 86%)
- Mortalité (20, 28%)

History of alcoholism ($n = 71$)	**No. (%) of patients**
Yes	29 (41)
No	8 (11)
Not reported	34 (48)
Prior pneumococcal vaccination ($n = 71$)	**No. (%) of patients**
Yes	6 (8)
No	7 (10)
Not reported	58 (82)
Temperature on admission ($n = 37$)	**(Degrees Celsius)**
Range	33.3–40.0
Mean	38.9
Level of consciousness on admission (GCS) ($n = 71$)	**No. (%) of patients**
Mild impairment (>12)	3 (4)
Moderate impairment (9–12)	6 (9)
Severe impairment (≤ 8)	12 (17)
Not reported	50 (70)
Presence of CNS signs on admission (n= 71)	**No. (%) of patients**
Yes	34 (48)
No	5 (7)
Not reported	32 (45)
Cardiac murmur heard on admission ($n = 71$)	**No. (%) of patients**
Yes	34 (48)
No	10 (14)
Not reported	27 (38)
Type of murmur ($n = 34$)	**No. (%) of patients**
Systolic	20 (58)
Diastolic	8 (24)
Mixed	2 (6)
Not reported	4 (12)

(Madu A et al, Clin Med 2024)

Facteurs de risque ?

- Etude multicentrique / 15 ans
- Âge 60 ± 14 ans, 38 H (76%)
  - 51 ans (IQR, 26-63), 71 H (64%)
- Peu de FDR EI
- 78% FDR infection à pneumocoque

(Périer A et al, Int J Cardiol 2019
de Egea V et al, Medicine 2015)

International Journal of Cardiology 288 (2019) 102–106

Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard

Prognosis of *Streptococcus pneumoniae* endocarditis in France, a multicenter observational study (2000–2015)☆

Amandine Périer [a,b], Mathieu Puyade [a,b], Matthieu Revest [c,d], Pierre Tattevin [c,d], Louis Bernard [e,f], Adrien Lemaignen [e,f], David Boutoille [g,h], Joseph Allal [a,i], France Roblot [a,j,k], Blandine Rammaert [a,j,k,*]

Table 1
Demographic and clinical characteristics of 50 patients with definite pneumococcal endocarditis.

Characteristics[a]	N = 50
Baseline	
Age at diagnosis (years), mean ± SD	60 ± 14
Male gender	38 (76)
IPD predisposing conditions	
Asplenia	2
>65 years	18 (36)
Chronic pulmonary disease	12 (24)
Repeated ENT infections	3
Cardiopathy	12 (24)
Alcoholism	17 (34)
Malignant blood disease	6
Renal failure	3
Kidney transplantation	1
IPD risk factors	
None	11 (22)
1	12 (24)
≥2	27 (54)
No vaccine uptake before IE	48 (96)
IE predisposing conditions	
Valvular prosthesis	5
Previous IE	1
Congenital cardiopathy	2
Valvular disease	10 (22)
Intravenous drug use	1
Pacemaker	4
IE risk factors	
None	38 (76)
1	6
≥2	6

Clinique et FDR ?

- 3251 adultes + IIP 2000-2014, Canada
- 28 EI (0.3%)
- **UDIV**
- Présentation clinique initiale + sévère (confusion mentale, USI; p<0,005)
- Souffle valvulaire nouveau 39.3% vs 2.2% si pas EI (p < 0.001)
- Mortalité 39.3% vs 14.7% IIP sans EI
- Pas de sérotype spécifique

(Marrie TJ et al, Eur J Clin Microbiol Infect Dis 2018)

Endocardite à pneumocoque ?

- Possible car fréquence = 10% des IE sur valve native ?
  - < 3%
- Peu probable car pas de FRD d'infection invasive à pneumocoque ?
  - Tabagisme et consommation excessive d'alcool
- Peu probable car pas de valve prothétique ?
  - Valve native
- Peu probable car pas de foyer de pneumonie ?
  - 1/2

Quel bilan complémentaire ?

- ETO ?
- IRM cérébrale ?
- TEP/TDM ?
- TDM abdominale ?

Intérêt ETO + ETT ?

European Journal of Echocardiography (2011) 12, 414–420
doi:10.1093/ejechocard/jer023

CLINICAL/ORIGINAL PAPERS

Prevalence of infective endocarditis in patients with *Staphylococcus aureus* bacteraemia: the value of screening with echocardiography

Rasmus V. Rasmussen[1*], Ulla Høst[2], Magnus Arpi[3], Christian Hassager[4], Helle K. Johansen[5], Eva Korup[6], Henrik C. Schønheyder[7], Jens Berning[8], Sabine Gill[9], Flemming S. Rosenvinge[10], Vance G. Fowler Jr[11], Jacob E. Møller[4], Robert L. Skov[12], Carsten T. Larsen[1], Thomas F. Hansen[1], Shan Mard[2], Jesper Smit[7], Paal S. Andersen[12], and Niels E. Bruun[1]

- 244 Bactériémies à S. aureus, 2009 – 2010
  - 53 EI certaines (22%)
  - Prévalence sur valve native 19%
  - Prévalence sur valve prothétique ou matériel intracardiaque 38%

- 92 patients ETT sans ETO
- 8 diagnostics d'EI sur ETT
- suivi à J30 : pas de nouveau diagnostic d'EI
- ETT de qualité « suffisante » dans un contexte où prévalence = 19%

Recommendations for the role of echocardiography in infective endocarditis		
A. Diagnosis		
TTE is recommended as the first-line imaging modality in suspected IE.	I	B
TOE is recommended in all patients with clinical suspicion of IE and a negative or non-diagnostic TTE.	I	B
TOE is recommended in patients with clinical suspicion of IE, when a prosthetic heart valve or an intracardiac device is present.	I	B
Repeating TTE and/or TOE within 5–7 days is recommended in cases of initially negative or inconclusive examination when clinical suspicion of IE remains high.	I	C
TOE is recommended in patients with suspected IE, even in cases with positive TTE, except in isolated right-sided native valve IE with good quality TTE examination and unequivocal echocardiographic findings.	I	C

Question 6: What Is the Role of an Echocardiogram in the Diagnosis of IE? (Clinical Review)

In most cases of suspected IE, obtaining an echocardiogram represents usual care. Nonetheless, like any test, echocardiography should be ordered when it will inform management decisions.

Both the pretest probability of IE and study quality strongly affect the impact of transthoracic echocardiography (TTE) on patient treatment. A negative TTE may be adequate to rule out native valve endocarditis (NVE) if the initial pretest probability[25,26] is low (eg, <10%), or with a high-quality study, even if the pretest probability is moderate (eg, <25%).

Transesophageal echocardiography (TEE) is more sensitive than TTE for the diagnosis of IE. A TEE is most useful in specific scenarios: (1) to reduce the possibility of NVE where an unacceptably high posttest probability remains after a negative TTE (eg, 5%-10%) and where eliminating the diagnosis will change patient treatment; (2) in the evaluation of PVE where TTE has a lower sensitivity; and/or (3) to facilitate surgical planning or to evaluate for specific complications (eg, perivalvular abscess).

Tep/TDM ?

Journal of *Clinical Medicine*

MDPI

Review

Contemporary Role of Positron Emission Tomography (PET) in Endocarditis: A Narrative Review

- **NVE :**
  - Sensibilité faible (31%), Spécificité **98%**
  - **Foyers à distance** (sauf cerveau)
- **PVE :**
  - **Sensibilité 84%, spécificité 86%**
  - Réponse au traitement ?
  - Foyers à distance (sauf cerveau)
- **TAVI** : > 1 mois après procédure
  - Analyse qualitative (répartition)
- **PM/défibrillateurs :**
  - Infection de générateur/poche sensibilité 93-96%, spécificité 97-98%
  - Sondes sensibilité 65-76%, spécificité 83-88%

(Sammartino AM et al, J Clin Med 2024)

TEP/TDM ?

Question 9: What Is the Role of Fluorodeoxyglucose PET in the Diagnosis and Management of IE? (Clinical Review)

Numerous observational studies have evaluated the accuracy of 2-[18F]-fluorodeoxyglucose (18-FDG)–PET/computed tomography (CT) for the diagnosis of NVE, PVE, and cardiac device-related IE (CDIE). Meta-analyses have reported the sensitivity of 18F-FDG-PET/CT for NVE as poor, especially compared with PVE and CDIE; however, specificity remains high. Specifically, the pooled sensitivity and specificity of 18F-FDG-PET/CT for NVE was reported as 31% and 82% vs 73% and 80% for PVE and 87% and 94% CDIE.[28-30] Given its low sensitivity, a negative 18F-FDG-PET/CT cannot rule out a diagnosis of NVE, even in cases where there is a low pretest probability. It may be reasonable at appropriately resourced centers to use 18F-FDG-PET/CT for strongly suspected cases of PVE or CDIE in the presence of a negative or nondiagnostic TTE or TEE.

The ability of 18F-FDG-PET/CT to affect clinical outcomes has not been assessed for IE specifically, but observational studies have suggested 18F-FDG-PET/CT may increase detection of occult, secondary seeded sites of infection during *S aureus* bacteremia.[31] 18F-FDG-PET/CT is resource-intensive, not routinely available in all centers, and exposes patients to ionizing radiation, and whether use improves outcomes remains unknown.

Recommendation Table 6 — Recommendations for the role of computed tomography, nuclear imaging, and magnetic resonance in infective endocarditis

Recommendations	Class[a]	Level[b]
Cardiac CTA is recommended in patients with possible NVE to detect valvular lesions and confirm the diagnosis of IE.[33,168,169]	I	B
[18F]FDG-PET/CT(A) and cardiac CTA are recommended in possible PVE to detect valvular lesions and confirm the diagnosis of IE.[22,129,209,210,237–239]	I	B
Cardiac CTA is recommended in NVE and PVE to diagnose paravalvular or periprosthetic complications if echocardiography is inconclusive.[20,168,169,185,186]	I	B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and/or MRI) are recommended in symptomatic[c] patients with NVE and PVE to detect peripheral lesions or add minor diagnostic criteria.[22,197–200,210,213,240,241]	I	B
WBC SPECT/CT should be considered in patients with high clinical suspicion of PVE when echocardiography is negative or inconclusive and when PET/CT is unavailable.[213–216]	IIa	C
[18F]FDG-PET/CT(A) may be considered in possible CIED-related IE to confirm the diagnosis of IE.[22,129,209,210,237,238]	IIb	B
Brain and whole-body imaging (CT, [18F]FDG-PET/CT, and MRI) in NVE and PVE may be considered for screening of peripheral lesions in asymptomatic patients.[188,197–201]	IIb	B

[18F]FDG-PET/CT, ^{18}F-fluorodeoxyglucose positron emission tomography/computed tomography; CAD, coronary artery disease; CT, computed tomography; CTA, computed tomography angiography; IE, infective endocarditis; MRI, magnetic resonance imaging; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; WBC SPECT/CT, white blood cell single photon emission tomography/computed tomography.

Quel bilan ?

née le 30/08/1953 - 69 ans à la date de l'examen

P Standard du 11/08/2023 (GIE Positon)

Identifiants
30081953
253533

TEP
GIE POSITON POITOU - CHARENTES

SERVICE D'IMAGERIE MOLECULAIRE – TEP

TEP au 18 FDG

Indication :
Recherche de foyer infectieux profond.

Technique :
TEP VISION 450 (Siemens N°1011) du 04/10/2019 ; Archivage PACS ; Glycémie 0.90 g/l ; Poids 66.0 kg; Taille 160 cm. Injection IV de 148 MBq de 18-FDG.
Scanner : PDL = 508 mGy.cm Prescription d'un régime hypoglucidique.

Résultats :

Etage sus-diaphragmatique :
Pas d'hyperfixation suspecte de la sphère ORL, des glandes mammaires, des aires ganglionnaires cervicales, médiastinohilaires ou axillaires.
Un foyer modérément hypermétabolique à la partie supérieure de la valve mitrale, suspect d'endocardite.
Pas de nodule pulmonaire solide hypermétabolique. Un nodule calcifié non métabolique du lobe moyen, d'allure séquellaire.

Etage sous-diaphragmatique :
Pas d'hyperfixation suspecte hépatique, splénique, surrénalienne, rénale, pancréatique, des anses digestives ou des aires ganglionnaires abdominopelviennes.
Un foyer modérément hypermétabolique au contact d'une plaque calcifiée de la partie proximale de l'artère iliaque primitive gauche : plaque instable ? Greffe septique ?



Quel traitement ?

- Amoxicilline 100 mg/kg/j pendant 4 semaines ?
- + Gentamicine 3 mg/kg pendant 2 semaines ?
- + Rifampicine
- Ceftriaxone 2 G / j
- Relais oral ?

Traitement ?

Table 2
Treatment and outcome of 50 patients with definite pneumococcal endocarditis.

	N = 50
Time from 1st symptoms onset to antibiotherapy, days (mean ± SD)	6.3 ± 6.9
Number of antibiotics, *n* (%)	
Monotherapy	7
Bitherapy	28 (56)
≥3 antibiotics	15 (30)
Antibiotic choice, *n* (%)	
3rd generation cephalosporin or amoxicillin or penicillin G or vancomycin	50 (100)
Gentamicin	39 (78)
Antibiotic duration (mean ± SD)	
Total antibiotherapy duration, weeks	5.5 ± 2.3
Beta-lactam or vancomycin duration, days	37 ± 14.7
Gentamicin duration, days	8.5 ± 8.4

ESC European Society of Cardiology
European Heart Journal (2023) **44**, 3948–4042
https://doi.org/10.1093/eurheartj/ehad193

2023 ESC Guidelines for the management of endocarditis

Traitement idem streptocoques oraux
CMI amoxicilline et ceftriaxone (≤ 0,5 mg/l)
Pas de schéma court
+ Gentamicine si CMI > 0,5 et ≤ 2 mg/l
Si méningite ceftriaxone ou vanco selon CMI
Relais oral J10 à J14

Recommendation Table 7 — Recommendations for antibiotic treatment of infective endocarditis due to oral streptococci and *Streptococcus gallolyticus* group

Recommendations		Class[a]	Level[b]
Penicillin-susceptible oral streptococci and *Streptococcus gallolyticus* group			
In patients with NVE due to oral streptococci and *S. gallolyticus*, penicilli…			
with gentamicin for 2 weeks is recommended using the following doses			
Adult antibiotic dosage and route			
Penicillin G	24 million U/day i.v. either in 4–6 dos…		
Amoxicillin	12 g/day i.v. in 4–6 doses		
Ceftriaxone	2 g/day i.v. in 1 dose		
Gentamicin	3 mg/kg/day i.v. or i.m. in 1 dose[d]		
In patients with PVE due to oral streptococci and *S. gallolyticus*, penicilli…			
gentamicin for 2 weeks is recommended using the following doses:[285–29…			
Adult antibiotic dosage and route			
Penicillin G	24 million U/day i.v. either in 4–6 doses or continuously	I	B
Amoxicillin	12 g/day i.v. in 4–6 doses		
Ceftriaxone	2 g/day i.v. in 1 dose		
Gentamicin[d]	3 mg/kg/day i.v. or i.m. in 1 dose[d]		

…axone are recommended for 4 — I B

…ed only for the treatment of …on using the following — I B

Penicillin G	12–18 million[c] U/day i.v. either in 4–6 doses or continuously		
Amoxicillin	12 g/day i.v. in 4–6 doses		
Ceftriaxone	2 g/day i.v. in 1 dose		
Gentamicin[d]	3 mg/kg/day i.v. or i.m. in 1 dose[d]		

Continued

Infectious diseases now 55 (2025) 105011

Contents lists available at ScienceDirect

Infectious Diseases Now

journal homepage: www.sciencedirect.com/journal/infectious-diseases-now

Guidelines

Antibiotic therapy and prophylaxis of infective endocarditis – A SPILF-AEPEI position statement on the ESC 2023 guidelines

GUIDELINE (see Fig. 1 and Table 3)

Susceptibility for the β-lactam chosen should be determined by its MIC measurement.

Antibiotic therapy is preferably based on monotherapy of either amoxicillin or ceftriaxone for 4–6 weeks when MIC is ≤0.5 mg/L.

Gentamicin should be associated for the first two weeks with high-dose amoxicillin when MIC is >0.5 mg/L and ≤2 mg/L.

Duration of antibiotic treatment should be four weeks in case of native valve IE (NVE) and six weeks in case of prosthetic valve IE (PVE).

In case of severe allergy to penicillin or resistance to both ceftriaxone (MIC > 0.5 mg/L) and amoxicillin (MIC > 2 mg/L), vancomycin should be used.

Endocarditis due to β-hemolytic streptococci, *S. anginosus* group streptococci and *S. pneumoniae* is relatively rare, and particularly severe. However, addition of gentamicin does not seem to be necessary when β-lactams are fully active, as it is toxic and not necessary to ensure bactericidal activity.

Quel traitement ?

- Amoxicilline 100 mg/kg perfusion continue
- Relais oral ?
- 400 EI coeur gauche
- 10 j de TTT ATBT IV
  - 199 IV
  - 201 relais oral
- Nombre de *S. pneumoniae* ?

The NEW ENGLAND JOURNAL of MEDICINE
ESTABLISHED IN 1812 JANUARY 31, 2019 VOL. 380 NO. 5

Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis

Table 1. Characteristics of the Patients at Baseline.*

Characteristic	Intravenous Treatment (N=199)	Oral Treatment (N=201)
Mean age — yr	67.3±12.0	67.6±12.6
Female sex — no. (%)	50 (25.1)	42 (20.9)
Body temperature — °C	36.9±0.45	37.0±0.44
Coexisting condition or risk factor — no. (%)		
Diabetes	36 (18.1)	31 (15.4)
Renal failure	25 (12.6)	21 (10.4)
Dialysis	13 (6.5)	15 (7.5)
COPD	17 (8.5)	9 (4.5)
Liver disease	7 (3.5)	6 (3.0)
Cancer	14 (7.0)	18 (9.0)
Intravenous drug use	3 (1.5)	2 (1.0)
Pathogen — no. (%)†		
Streptococcus	104 (52.3)	92 (45.8)
Enterococcus faecalis	46 (23.1)	51 (25.4)
Staphylococcus aureus‡	40 (20.1)	47 (23.4)
Coagulase-negative staphylococci	10 (5.0)	13 (6.5)

Quel traitement ?

- Pas de différence à 6 mois
  - Mortalité
  - Embols
  - Chirurgie cardiaque en urgence
  - Rechute de bactériémie

Table 2. Distribution of the Four Components of the Primary Composite Outcome.*

Component	Intravenous Treatment (N=199)	Oral Treatment (N=201)	Difference	Hazard Ratio (95% CI)
	number (percent)		*percentage points (95% CI)*	
All-cause mortality	13 (6.5)	7 (3.5)	3.0 (−1.4 to 7.7)	0.53 (0.21 to 1.32)
Unplanned cardiac surgery	6 (3.0)	6 (3.0)	0 (−3.3 to 3.4)	0.99 (0.32 to 3.07)
Embolic event	3 (1.5)	3 (1.5)	0 (−2.4 to 2.4)	0.97 (0.20 to 4.82)
Relapse of the positive blood culture†	5 (2.5)	5 (2.5)	0 (−3.1 to 3.1)	0.97 (0.28 to 3.33)

* Six patients, three in each group, had two outcomes.
† For details about relapse of the positive blood culture, see the Supplementary Appendix.



Figure 2. Kaplan–Meier Plot of the Probability of the Primary Composite Outcome.

The primary composite outcome was all-cause mortality, unplanned cardiac surgery, embolic events, or relapse of bacteremia with the primary pathogen, from randomization until 6 months after antibiotic treatment was completed. The oral treatment group shifted from intravenously administered antibiotics to orally administered antibiotics at a median of 17 days after the start of treatment. The inset shows the same data on an enlarged y axis.

Et à 5 ans ?

Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial



Figure 1. Cumulative Incidence of Events.

Shown are plots of the cumulative incidence of events from randomization to a median follow-up of 5.4 years. The patients assigned to the intravenous treatment group received intravenous antibiotic therapy for the entire treatment period, and the patients assigned to receive step-down treatment shifted from intravenous antibiotics to oral antibiotics after clinical stabilization was reached. The composite primary outcome consisted of death from any cause, unplanned cardiac surgery, embolic events, and relapse of a blood culture result positive for the primary pathogen.

	Relai oral de 1ère ligne	Relai oral en alternative
Streptococcus spp.	Amoxicilline + rifampicine ou Amoxicilline + moxifloxacine	Attente des résultats de l'essai RODEO Amoxicilline
Enterococcus faecalis	Amoxicilline + moxifloxacine	Attente des résultats de l'essai RODEO Amoxicilline
Staphylococcus spp.	Attente des résultats de l'essai RODEO Rifampicine + levofloxacine	Cotrimoxazole
BGN	Ciprofloxacine	

Antibiotique oral	Dosage si patient ≤ 70kg	Dosage si patient > 70kg
Amoxicilline	1.5g* 3 /jour	2g *3 / jour
Rifampicine	600mg *1 /jour	900mg* 1/ jour
Moxifloxacine	400mg *1 / jour	400mg* 1/jour
Levofloxacine	500mg *1 /jour	750mg *1/ jour

(Strady C et al. Infect Dis Now 2025)

Pronostic

International Journal of Cardiology 288 (2019) 102–106

Contents lists available at ScienceDirect

International Journal of Cardiology

journal homepage: www.elsevier.com/locate/ijcard

Prognosis of *Streptococcus pneumoniae* endocarditis in France, a multicenter observational study (2000–2015)☆

Amandine Périer [a,b], Mathieu Puyade [a,b], Matthieu Revest [c,d], Pierre Tattevin [c,d], Louis Bernard [e,f], Adrien Lemaignen [e,f], David Boutoille [g,h], Joseph Allal [a,i], France Roblot [a,j,k], Blandine Rammaert [a,j,k,*]

- Chirurgie dans la semaine suivant le diagnostic (28, 60%; délai 6.5 j [2.0-10.5]
- Taux de survie à J90 : 83% (n=33)
  - 7 décès dont 6 liées à l'EI
  - 5 EI sur valve prothétique: 3 décès délai 22j (21-40,5)
  - 2 rechutes 48H et 6 mois après arrêt ATBT

- Taux de survie à 2 ans : 67% (n=28)
  - 5 décès
  - Âge > 65 ans (p<0,001)
  - Chirurgie "protectrice" (15 vs 6; p = 0.012)
  - Méningite ns, Austrian syndrome ns

- 50% des décès directement liés à l'EI

Pronostic

- Etude cas/témoins (23 ans, monocentrique)
- 28 EI à pneumocoque / 56 EI autres causes
  (21 *S. aureus*)
- Alcoolisme et tabagisme
- Absence de valvulopathie
- Gravité clinique : choc et insuffisance cardiaque
- Chirurgie cardiaque 64,3%
  - précoce (14.1 ± 18.2 versus 69.0 ± 61.1 j)

(M. Daudin et al, Clin Microbiol Infect 2016)

TABLE I. Comparison of pneumococcal endocarditis (cases), and non-pneumococcal infective endocarditis (controls[a])

Characteristics	Pneumococcal endocarditis (n = 28)	Endocarditis due to other bacteria (n = 56)	p value
Baseline			
Age (years), mean ± SD	59.1 ± 15.3	60.9 ± 15.3	NS
Male gender, n (%)	19 (67.8)	40 (71.4)	NS
Alcoholism, n (%)	11 (39.3)	6 (10.7)	<0.01
Smoking, n (%)	17 (60.7)	12 (21.4)	< 0.01
Previously known valvular disease, n (%)	5 (17.9)	22 (39.3)	0.047
Valve(s) involved, n (%)			
Aortic	19 (70.4)	35 (62.5)	NS
Mitral	10 (37.0)	28 (50.0)	NS
Tricuspid	3 (11.1)	2 (3.6)	NS
Pulmonary	1 (3.7)	0 (0)	NS
Two or more valves	4 (14.8)	9 (16.1)	NS
Peri-valvular abscess	8 (34.8)	17 (30.4)	NS
Cardiac surgery, n (%)	18 (64.3)	31 (55.4)	NS
Time from symptoms onset to surgery, days ± SD	14.1 ± 18.2	69.0 ± 61.1	<0.001
Time from admission to surgery, days ± SD	13.3 ± 17.1	34.3 ± 43.0	0.02
Complications, n (%)			
Shock	15 (53.6)	13 (23.2)	<0.01
Heart failure[b]	18 (64.3)	13 (23.2)	<0.01
Embolism	5 (17.9)	16 (28.6)	NS
Meningitis	8 (28.6)	3 (5.4)	<0.01
In-hospital mortality	2 (7.1)	7 (12.5)	NS
5-year mortality	11 (39.3)	10 (17.9)	NS

Abbreviations: NS, not significant; SD, standard deviation.
[a]Controls were endocarditis due to *Staphylococcus aureus* (n = 21), non-pneumococcal *Streptococcus* spp. (n = 20), *Enterococcus* spp. (n = 8), other Gram-positive cocci (n = 4) and Gram-negative bacilli (n = 3).

Pronostic

- Mortalité à 5 ans 54,1%



FIG. 1. Kaplan–Meier curve for cumulative survival probability.

(M. Daudin et al, Clin Microbiol Infect 2016)

Quelle prévention ?



- Vaccination anti pneumococcique ?
- Si FDR d'infection invasive à pneumocoque ou ≥ 65 ans

b) Patients non immunodéprimés porteurs d'une maladie sous-jacente prédisposant à la survenue d'Infection Invasive à Pneumocoque (IIP) :

- Cardiopathie congénitale cyanogène, insuffisance cardiaque ;
- Insuffisance respiratoire chronique, bronchopneumopathie obstructive, emphysème ;
- Asthme sévère sous traitement continu ;
- Insuffisance rénale ;
- Hépatopathie chronique d'origine alcoolique ou non ;
- Diabète non équilibré par le simple régime ;
- Patients présentant une brèche ostéo-méningée, un implant cochléaire ou candidats à une implantation cochléaire.

- Pas au décours d'une IIP en l'absence de FDR

Conclusion

- Rare mais ça existe
- Grave
- Peu FDR EI
- Facteurs de virulence spécifiques des *S. pneumoniae* ?
- Traitement oral ?

Cours Approfondi de Chimiothérapie Infectieuse et Vaccinologie

Atelier ‘Endocardites infetcieuses’

Prof. Pierre Tattevin

Maladies Infectieuses et Réanimation Médicale, INSERM U 835

Hôpital Pontchaillou, CHU Rennes

CHU Rennes

Université de Rennes

AEPEI: Association pour l’ Etude et la Prévention des Endocardites Infectieuses

ICE International Collaboration on Endocarditis

Liens d’intérêt: conseils scientifiques (2020-2025)

- Pfizer
- Advanz
- Gilead
- Basiléa
- Shionogi
- Simon Kuscher

‘Un médecin qui connait bien l’ endocardite connait bien toute la médecine’

William Osler, 1888





2023 ESC Guidelines for the management of endocarditis

Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC)

Delgado V et al. Eur Heart J 2023

Guidelines

Antibiotic therapy and prophylaxis of infective endocarditis – A SPILF-AEPEI position statement on the ESC 2023 guidelines

Strady C et al. Infect Dis Now 2025

Blood Culture-Negative Endocarditis

A Scientific Statement of the American Heart Association

Simone DC et al. J Am Heart Assoc 2025

Cas clinique

- Mr Z, 66 ans
- ATCD
  - HTA sous captopril
  - Ulcère de jambe chronique
- AEG fébrile depuis 3 jours + dyspnée
- Admission
  - T = 39° C, TA = 110/60 mmHg
  - Multiples lésions purpuriques
  - Souffle IM 3/6 non connu
  - Crépitants des 2 bases

Echocardiographie

- Fuite mitrale 2/4
- FEVG 50%
- Végétation feuillet antérieur 10 mm



Votre prescription d'hémocultures

1. 2 paires bien remplies
2. 3 paires bien remplies
3. Lors d'une seule ponction
4. Espacées de 30 minutes
5. Sur milieux spéciaux

Votre prescription d'hémocultures

1. 2 paires bien remplies
2. **3 paires <u>bien remplies</u>**
3. **Lors d'une seule ponction**
4. Espacées de 30 minutes
5. Sur milieux spéciaux

How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art

Brigitte Lamy[1†], Sylvie Dargère[2†], Maiken C. Arendrup[3], Jean-Jacques Parienti[4] and Pierre Tattevin[5]*

Sensibilité hémocultures pour le diagnostic d'EI

20 mL : 65 -70 %

40 mL : 80 - 90 %

60 mL : 96 - 98 %

3 paires bien remplies avant tout ATB => Sensibilité >95%

Lamy B et al. Front Microbiol 2016

How to Optimize the Use of Blood Cultures for the Diagnosis of Bloodstream Infections? A State-of-the Art

Brigitte Lamy[1†], Sylvie Dargère[2†], Maiken C. Arendrup[3], Jean-Jacques Parienti[4] and Pierre Tattevin[5]*

TABLE 3 | Quality of bottle filling.

	Under-filled bottles		
References	**Threshold (mL)**	**Rate (%)**	**Country**
Vitrat-Hincky et al., 2011	< 8	65	France
Willems et al., 2012[a,b]	< 8	26.2–36.0	Belgium
van Ingen et al., 2013	< 8	55.3	The Nederlands
Coorevits and Van den Abeele, 2015	< 8	28.0	Belgium
Chang et al., 2015	< 8	97.7	South Korea
Lin et al., 2013	< 7	28.3	Taiwan
Mermel and Maki, 1993	< 5	20	USA
Chang et al., 2015	< 3	48.4	South Korea

Lamy B et al. Front Microbiol 2016

BMJ Quality Improvement report

Education and coaching to optimise blood culture volumes: continuous quality improvement in microbiology

Keith A Sacco,[1] Joy H Peterson,[2] Claudia R Libertin[3]



Figure 1 Mean blood culture volumes over time. The arrow depicts initiation of education and coaching of phlebotomists. The mean volume increased and then stayed consistently increased after the education intervention in May 2015.

Sacco KA et al. BMJ Quality Open 2018

Active Monitoring and Feedback to Improve Blood Culture Fill Volumes and Positivity Across a Large Integrated Health System

Reeti Khare,[1,2] Tarush Kothari,[2,3] Joseph Castagnaro,[3] Bryan Hemmings,[2,3] May Tso,[3] Stefan Juretschko[1,2]



Khare R et al. Clin Infect Dis 2020

Active Monitoring and Feedback to Improve Blood Culture Fill Volumes and Positivity Across a Large Integrated Health System

Reeti Khare,[1,2] Tarush Kothari,[2,3] Joseph Castagnaro,[3] Bryan Hemmings,[2,3] May Tso,[3] Stefan Juretschko[1,2]





Khare R et al. Clin Infect Dis 2020

Effectiveness of a multimodal intervention to improve blood culture collection in an adult emergency department

Alexis Merien[1] · Astrid Bacle[2] · Pierre Tattevin[3] · Dorsaf Bellasfar[1] · Caroline Piau[3] · Vincent Cattoir[3] · Louis Soulat[1] · Yannick Malledant[4] · Ronan Garlantezec[2]



Merien A et al. Eur J Clin Microbiol Infect Dis 2023

Effectiveness of a multimodal intervention to improve blood culture collection in an adult emergency department

Alexis Merien[1] · Astrid Bacle[2] · Pierre Tattevin[3] · Dorsaf Bellasfar[1] · Caroline Piau[3] · Vincent Cattoir[3] · Louis Soulat[1] · Yannick Malledant[4] · Ronan Garlantezec[2]

Supplementary Material VI Patient characteristics and appropriateness of blood cultures before (first months of 2021 as a reference) and after the intervention

	Pre-intervention period	Post-intervention period	*P* value
Number of patients	8 584	25 977	
Number of patients with at least one pair of blood cultures sampled	624 (7.27%)	1 080 (4.2%)	<0.0001
Appropriateness of blood cultures sampling per hospital stay			
No	491 (78.7%)	336 (31.1%)	
Yes	133 (21.3%)	744 (68.9%)	<0.0001
Solitary blood culture *			
No	229 (36.7%)	978 (90.6%)	
Yes	395 (63.3%)	102 (9.4%)	<0.0001
Appropriate volume for each bottle			
No	231 (37.0%)	185 (17.1%)	
Yes	393 (63.0%)	895 (82.9%)	<0.0001

Merien A et al. Eur J Clin Microbiol Infect Dis 2023

2024 ISCVID

UniEndo

Single-sampling strategy for blood cultures in the diagnosis of infective endocarditis: the prospective multicenter UniEndo study

Single Sampling Strategy (SSS)

Vs.

Multiple Sampling Strategy (MSS)

Goehringer F et al. Clin Infect Dis 2025

UniEndo NCT03153384

- **Prospective multicenter study** (8 tertiary-care hospitals)
- **Enrolling consecutive patients suspected of IE**

  - At least one major or two minor non-microbiologic criteria (2015 ESC)
  - Absence of microbiological result available at the time of enrolment
  - Antibiotics for IE <24 hours or stopped >7 days at the time of enrolment

- **SSS and MSS were performed for all patients**



- 256 patients enrolled, median age 70
  - 49% Prosthetic valvular material
  - Fever 60%
  - Heart failure 30%
  - Embolic event 10%

- **IE= 101 (39%)**

Goehringer F et al. Clin Infect Dis 2025

UniEndo

Patients with a variation depending on SSS or MSS of the microbiological criterion according to 2015 ESC criteria (n=14)



⇒Single sampling of 6 blood culture bottles (60 mL) in patients with suspected IE

Better diagnostic yield, earlier start of empirical ATB when indicated
Cheaper, less pain for patients, decreased workload for nurses…

Strady C et al. Infect Dis Now 2025

Autre(s) test(s) microbiologique(s) ?

1. Sérologie fièvre Q
2. Hémocultures fongiques
3. Demande cultures prolongées
4. PCR multiplex ‘septifast’
5. Sérologie *Bartonella* sp.
6. Nope

Autre(s) test(s) microbiologique(s) ?

1. Sérologie fièvre Q
2. Hémocultures fongiques
3. Demande cultures prolongées
4. PCR multiplex ‘septifast’
5. Sérologie *Bartonella* sp.
6. **Nope**

Blood Culture–Negative Endocarditis: A Scientific Statement From the American Heart Association

Endorsed by the International Society for Cardiovascular Infectious Diseases

Daniel C. DeSimone, MD, Chair; Zerelda Esquer Garrigos, MD, Vice Chair; Grace E. Marx, MD, MPH; Pierre Tattevin, MD; Barbara Hasse, MD; David W. McCormick, MD; Margaret M. Hannan, MD; Liesl J. Zuhlke, MD; Connie S. Radke, MSN, NP; Larry M. Baddour, MD, FAHA; on behalf of the American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research



Simone DC et al. J Am Heart Assoc 2025

BCNE: highlights

- **In most cases, BCNE is a failure, due to inappropriate use of ATB and/or sub-optimal diagnostic tests**
- **Appropriate sampling of blood culture bottles in patients suspected of infective endocarditis (IE) is key**
- **Which implies:**
  - Early access to trained health care workers
  - Effective antimicrobial stewardship program
  - Appropriate sampling of blood cultures bottles when prescribed

Simone DC et al. J Am Heart Assoc 2025

Outcomes of culture-negative vs. culture-positive infective endocarditis: the ESC-EORP EURO-ENDO registry

William K.F. Kong [1,2†], Antonio Salsano [3,4*†], Daniele Roberto Giacobbe [5,6†], Bogdan A. Popescu [7], Cécile Laroche[8], Xavier Duval[9,10], Robert Schueler[11], Antonella Moreo [12], Paolo Colonna [13], Cornelia Piper[14], Francisco Calvo-Iglesias [15], Luigi P. Badano [16,17], Ilija Srdanovic[18,19], David Boutoille [20], Olivier Huttin [21,22,23], Elisabeth Stöhr[11], Ana Teresa Timóteo [24,25,26], Jolanta-Justina Vaskelyte [27], Anita Sadeghpour [28,29], Pilar Tornos [30], Leila Abid [31], Kian Keong Poh [1,2], Gilbert Habib [32,34], and Patrizio Lancellotti [28] on behalf of the EURO-ENDO Investigators

Results

1. CNIE patients presented less comorbidities than patients with CPIE on admission. Heart failure due to valvular dysfunction was more frequently observed in patients with CNIE
2. 30-day mortality was approximately 5% higher in CNIE than CPIE patients
3. CNIE patients with theoretical surgical indications were less frequently operated on than CPIE patients
4. CNIE was associated with 1-year mortality
5. 1-year survival was lower for CNIE than CPIE in patients receiving medical treatment alone and comparable between CNIE and CPIE in surgically treated patients



Kong WKF et al. Eur Heart J 2022

Temporal Trends in Infective Endocarditis in the Context of Prophylaxis Guideline Modifications

Three Successive Population-Based Surveys

Xavier Duval, MD, PhD,*†‡ François Delahaye, MD, PhD,§‖ François Alla, MD, PhD,¶#
Pierre Tattevin, MD, PhD,** Jean-François Obadia, MD, PhD,†† Vincent Le Moing, MD, PhD,‡‡§§
Thanh Doco-Lecompte, MD,¶ Marie Celard, MD,‖‖ Claire Poyart, MD, PhD,¶¶##***
Christophe Strady, MD, PhD,††† Catherine Chirouze, MD,‡‡‡ Michelle Bes, PhD,‖‖
Emmanuelle Cambau, MD, PhD,‡§§§ Bernard Iung, MD,‡‖‖‖ Christine Selton-Suty, MD,¶
Bruno Hoen, MD, PhD,‡‡‡¶¶¶ on behalf of the AEPEI Study Group

- **Population-based prospective cohort studies**
  - 1991 (n=323): 13% BCNE
  - 1999 (n=331): 7% BCNE
  - 2008 (n=339): 7% BCNE



Duval X et al. J Am Coll Cardiol 2015

Open Access Full Text Article

REVIEW

Blood Culture Negative Endocarditis: A Review of Laboratory Diagnostic Approaches

Kuan-Pei Lin[1], Ting-Kuang Yeh[1,2], Yu-Chuan Chuang[1], Li-An Wang[1], Yun-Ching Fu[3,4]*, Po-Yu Liu[1,4–6]*

Table 1 Studies Using Serologic Tests for the Diagnosis of Blood Culture Negative Endocarditis

Country	Duration	Number	Sample	Pathogen
France[1]	1983–2001	348 (268/348)	Serology	*Coxiella burnetii* (167) *Bartonella sp* (99) *Mycoplasma hominis* (1) *Legionella pneumophila* (1)
France[16]	1994–2004	248 (36/248)	Serology	*Coxiella burnetii* (27) *Bartonella sp* (5) *Legionella pneumophila* (2) *Aspergillus sp* (1) *Chlamydia* (1)
France[17] UK Algeria	2001–2009	745 (356/745)	Serology	*Coxiella burnetii* (274) *Bartonella sp* (80) *Legionella pneumophila* (1) *Legionella anisa* (1)
France[4]	2010–2015	283 (41/283)	Serology	*Coxiella burnetii* (23) *Bartonella quintana* (13) *Bartonella henselae* (4) *Legionella pneumophila* (1)

Lin KP et al. Clin Gen Med 2023

Open Access Full Text Article

REVIEW

Blood Culture Negative Endocarditis: A Review of Laboratory Diagnostic Approaches

Kuan-Pei Lin[1], Ting-Kuang Yeh[1,2], Yu-Chuan Chuang[1], Li-An Wang[1], Yun-Ching Fu[3,4]*, Po-Yu Liu[1,4–6]*

Table 2 Studies Using Specific PCR Method for the Diagnosis of Blood Culture-Negative Endocarditis

Country	Duration	Number	Sample	Pathogen
France[1]	1983–2001	348 (88/348)	Valve	*Coxiella burnetii* (41) *Bartonella* (47)
France[4]	2010–2015	283 (45/283)	Valve	*Bartonella henselae (2)* *Bartonella quintana (2)* *Coxiella burnetii (3)* *Tropheryma whippelii (2)* *Enterococcus faecalis (8)* *Enterococcus faecium (2)* *Mycoplasma hominis (1)* *Staphylococcus aureus (10)* *Streptococcus gallolyticus (12)* *Streptococcus infantarius (1)* *Streptococcus oralis (2)*
Switzerland[60]	2018	1 (1/1)	Valve	*Cardiobacterium hominis (1)*

Lin KP et al. Clin Gen Med 2023

Non-bacterial thrombotic endocarditis

<1% of all endocarditis

1. **Cancer**
   (adenocarcinoma)

2. **Autoimmune**
   SLE and/or APL Sd



Ahmed O et al. Eur Heart J 2025

Prolonged Incubation and Extensive Subculturing Do Not Increase Recovery of Clinically Significant Microorganisms from Standard Automated Blood Cultures

Ellen Jo Baron,[1,2] John D. Scott,[3] and Lucy S. Tompkins[1,2]



An extensive blood culture protocol, including prolonged incubation of cultures, for 215 patients believed to have had endocarditis yielded only 3 clinically relevant results. Twenty-four *Haemophilus*, *Actinobacillus*, *Cardiobacterium*, *Eikenella*, and *Kingella* (i.e., HACEK) organisms were recovered from standard 5-day blood cultures during the same time

Baron et al. Clin Infect Dis 2005

Stanford protocol 1994-99

Original medium, subculture medium[a]	Total duration of incubation	Acridine orange staining performed on days 3 and 10
Bactec Aerobic Plus 26 bottles (n = 3)	3 weeks	Yes
BCYE	2 weeks	…
Chocolate agar (n = 2)	3 weeks	…
Rabbit blood agar	3 weeks	…
Sabouraud dextrose agar	4 weeks	…
Lowenstein-Jensen agar	6 weeks	…
Bactec Anaerobic Plus 27 bottles (n = 3)	3 weeks	Yes
BCYE	2 weeks	…
Chocolate agar (n = 2)	3 weeks	…
Rabbit blood agar	3 weeks	…
Sabouraud dextrose agar	4 weeks	…
Lowenstein-Jensen agar	6 weeks	…
Anaerobic brucella blood agar	6 days	…
Adult Isolator tubes (n = 4)	…	No
BCYE	2 weeks	…
Chocolate agar	3 weeks	…
Rabbit blood agar	3 weeks	…
Sabouraud dextrose agar	4 weeks	…
Lowenstein-Jensen agar	6 weeks	…
Anaerobic brucella blood agar	6 days	…

Clinical Characteristics and Outcomes of Patients With *Cutibacterium acnes* Endocarditis

Floris J. Heinen, MD; Florent Arregle, MD; Floris S. van den Brink, MD, PhD; Nina Ajmone Marsan, MD, PhD; Lucas Bernts, MD, PhD; Patrick Houthuizen, MD, PhD; Otto Kamp, MD, PhD; Nienke Roescher, MD, PhD; Naomi Timmermans, MD; Nelianne Verkaik, MD, PhD; Jolien Roos-Hesselink, MD, PhD; Marco C Post, MD, PhD; Gilbert Habib, MD, PhD; Wilco Tanis, MD, PhD

- Retrospective study, the Netherlands/France, 2010-2020
  - 105 patients with definite *C. acnes* endocarditis (7 sites)
  - Mean age, 61 years / 91% males / 89% PVE
  - **Median time to positive BC: 7 days (IQR 6-9)**

Heinen FJ et al. JAMA Network Open 2023

Blood Culture–Negative Endocarditis: A Scientific Statement From the American Heart Association



Simone DC et al. J Am Heart Assoc 2025

Comparison of Blood-Based Shotgun and Targeted Metagenomic Sequencing for Microbiological Diagnosis of Infective Endocarditis

Laure Flurin,[1,2,3] Cody R. Fisher,[1,3] Matthew J. Wolf,[1,3] Bobbi S. Pritt,[3] Daniel C. DeSimone,[3] and Robin Patel[1,3]

	Positive Blood Culture Result at Time of Study Blood Draw	Any Positive Blood Culture	Positive Karius Test	Positive tMGS
Total (n = 34)	7 (21)	28 (82)	24 (71)	22 (65)
BCPE (n = 28)	7 (25)	28 (100)	21 (75)	17 (61)
BCNE (n = 6)	0 (–)	0 (–)	3 (50)	5 (83)



NB. Commercial shotgun ‘Karius’: 2000 USD/sample

Flurin L et al. Open Forum Infect Dis 2023

Leçon n°1: rester simple !

- **3 paires d'hémocultures *avant antibiothérapie***
  - 10 ml/flacon, aéro + anaérobies
  - > 90% des diagnostics
  - dans des délais 'standards' (< 5 jours)

- **Pas de nécessité d'avertir le laboratoire à J0**

- **Aucune sérologie n'est indiquée**

CAT si EI probable, mais hémocultures négatives 48-72 h

- **Prolongation incubation hémocultures**
- **Sérologies *Bartonella* spp. et fièvre Q**
- **Prélèvement pour métagénomique ?**
- **Revoir le dossier ‘à fond’**
  - **forte VPN** de 3 hémoc si pas d’ATB avant
  - hypothèse 1 = **ce n’est pas une EI**
  - sinon, chasser les ‘moutons à 5 pattes’

Cas clinique

- Mr Z, 66 ans
- ATCD
  - Ulcère de jambe chronique

- AEG fébrile depuis 3 jours + dyspnée
- Admission
  - T = 39° C, TA = 110/60 mmHg
  - Multiples lésions purpuriques
  - Crépitants des 2 bases
- ETT
  - IM 2/4 avec végétation 10 mm



Quel(s) traitement(s) instaurez vous?

1. amoxicilline + gentamicine
2. amoxicilline + (cl)oxacilline + gentamicine
3. amoxicilline + céfazoline
4. amoxicilline-acide clavulanique + gentamicine
5. amoxicilline + ceftriaxone
6. on attend les hémocultures

Quel(s) traitement(s) instaurez vous?

1. amoxicilline + gentamicine
2. amoxicilline + (cl)oxacilline + gentamicine
3. **amoxicilline + céfazoline**
4. amoxicilline-acide clavulanique + gentamicine
5. amoxicilline + ceftriaxone
6. on attend les hémocultures

Traitements empiriques

Contexte

Cibles:

1. **staphylocoques (35%)**
2. **streptocoques (35%)**
3. **entérocoques (10%)**
4. divers (15%)
5. EI non documentées (5%)





Selton-Suty C et al. Clin Infect Dis 2012

Recos anciennes (US 2005 & Europe 2009)

- **EI communautaire** => péni A / inhibiteur bêta-lactamase + gentamicine
- **EI précoce (< 1 an) sur prothèse** => vancomycine + gentamicine + rifampicine
- **EI tardive sur prothèse (> 1 an)** = idem EI communautaire valve native

Traitements empiriques: recos USA 2015

- Rationnel
  - Trop d'antibiothérapie 'intempestive' pour suspicion d'EI
  - Rarement une urgence immédiate
  - Complexité croissante

⇒ **Pas de schéma empirique standard**

⇒ **Avis infectieux** (on a le temps !)

⇒ **Tableaux, tenant compte du contexte, de l'évolutivité, etc.**

Baddour LM et al. Circulation 2015

Traitements empiriques: recos Europe 2015

Table 20 Proposed antibiotic regimens for initial empirical treatment of infective endocarditis in acute severely ill patients (before pathogen identification)[a]

Antibiotic	Dosage and route	Class[b]	Level[c]	Comments
Community-acquired native valves or late prosthetic valves (≥12 months post surgery) endocarditis				
Ampicillin with (Flu)cloxacillin *or* oxacillin with Gentamicin[d]	12 g/day i.v. in 4–6 doses 12 g/day i.v. in 4–6 doses 3 mg/kg/day i.v. or i.m. in 1 dose	IIa	C	Patients with BCNIE should be treated in consultation with an ID specialist.
Vancomycin[d] with Gentamicin[d]	30–60 mg/kg/day i.v. in 2–3 doses 3 mg/kg/day i.v. or i.m. in 1 dose	IIb	C	For penicillin-allergic patients
Early PVE (<12 months post surgery) or nosocomial and non-nosocomial healthcare associated endocarditis				
Vancomycin[d] with Gentamicin[d] with Rifampin	30 mg/kg/day i.v. in 2 doses 3 mg/kg/day i.v. or i.m. in 1 dose 900–1200 mg i.v. or orally in 2 or 3 divided doses	IIb	C	Rifampin is only recommended for PVE and it should be started 3–5 days later than vancomycin and gentamicin has been suggested by some experts. In healthcare associated native valve endocarditis, some experts recommend in settings with a prevalence of MRSA infections >5% the combination of cloxacillin plus vancomycin until they have the final S. aureus identification

Habib G et al. Eur Heart J 2015

The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: An analysis from the ICE Prospective Cohort Study (ICE-PCS)



Daily incidence of stroke in ICE cohort.

Dickerman SA et al. Am Heart J 2007

The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: An analysis from the ICE Prospective Cohort Study (ICE-PCS)



Stroke rate after initiation of antimicrobial therapy.

Dickerman SA et al. Am Heart J 2007

Are all beta-lactams similarly effective in the treatment of methicillin-sensitive *Staphylococcus aureus* bacteraemia?

M. Paul[1,2], N. Zemer-Wassercug[1], O. Talker[1], Y. Lishtzinsky[1], B. Lev[3], Z. Samra[3,2], L. Leibovici[4,2] and J. Bishara[1,2]

TABLE 2. Multivariable logistic regression analysis for 30-day mortality: empirical antibiotic treatment[a]

Variable[b]	OR, 95% CI *n* = 541 patients, deaths = 202	p-value
Empirical antibiotic treatment		
Oxacillin/cefazolin	Reference	
Cefuroxime	1.98 (0.98–4.01)	0.058
Ceftriaxone/cefotaxime	2.24 (1.23–4.08)	0.008
Beta-lactam-beta-lactamase	2.68 (1.23–5.85)	0.013

Paul M et al. Clin Microbiol Infect 2011

Factors associated with 12 week case-fatality in *Staphylococcus aureus* bacteraemia: a prospective cohort study

P. Braquet [1,2,*], F. Alla [3,4,5], C. Cornu [6,7,8], F. Goehringer [9], L. Piroth [10], C. Chirouze [11], M. Revest [12], C. Lechiche [13], X. Duval [14,15,16], V. Le Moing [1,2,*], on behalf of the VIRSTA-AEPEI study group

CMI CLINICAL MICROBIOLOGY AND INFECTION
ESCMID

- **Cohorte VIRSTA**

  - Prospective, observationnelle
  - France, 2009-2011
  - 2091 bactériémies *S. aureus*
  - **Létalité**
    - **23% à S4**
    - **34% à S12**



Braquet P et al. Clin Microbiol Infect 2016

Messages – traitement empirique

1. SAMS = ennemi public n° 1
   - Il faut que le schéma comprenne (cl)oxa ou céfazo

2. Couverture des 2 autres ‘usual suspects’
   - amoxicilline pour les streptocoques
   - bactéricide sur *E. faecalis* si combiné à céfazoline

Amoxicilline (200 mg/kg/j) + céfazoline (100 mg/kg/j)

Synergistic effect of Amoxicillin and cefotaxime against *Enterococcus faecalis*

Mainardi *et al.* Antimicrob. Agents Chemother 1995







Saturation de PLP différentes par l'amoxicilline et le céfotaxime

Mainardi JL et al. Antimicrob Agents Chemother 1995

In vitro bactericidal activity of amoxicillin combined with different cephalosporins against endocarditis-associated *Enterococcus faecalis* clinical isolates

Nathan Peiffer-Smadja[1,2]†, Elena Guillotel[3]†, David Luque-Paz[3], Naouale Maataoui[2,4], F.-Xavier Lescure[1,2] and Vincent Cattoir [3,5,6]*



Peiffer-Smadja N et al. J Antimicrob Chemother 2019

Cas clinique (suite)

- Deux hémocultures sont positives à *Staphylococcus aureus*
- PLP 2A négative



Quel(s) traitement(s) prescrivez vous ?

1. (cl)oxacilline
2. (cl)oxacilline + gentamicine
3. céfazoline + gentamicine
4. triméthoprime-sulfaméthoxazole + clindamycine
5. daptomycine
6. céfazoline

Quel(s) traitement(s) prescrivez vous ? Réponses

1. **(cl)oxacilline**
2. (cl)oxacilline + gentamicine
3. céfazoline + gentamicine
4. triméthoprime-sulfaméthoxazole + clindamycine
5. daptomycine
6. **céfazoline**

Faut-il opérer toutes les EI à *S. aureus* , comme préconisé par les recos ESC 2023 ?

Reference	Country, study period	Number of patients with *S. aureus* IE	Proportion of IE patients treated with cardiac surgery	Outcome
Rasmussen M et al, Scand J Infect Dis 2009	Denmark and Sweden, 1996-2008	170	40.6% (69/170)	1-year mortality 39%
Chirouze C et al, Clin Infect Dis 2014	International (28 countries), 2000-2006	168	44.0% (74/168) within the first 60 days	1-year mortality - 33.8% (25/74) in surgical patients - 59.1% (55/93) in patients without early surgery
Lecomte R et al, Clin Microbiol Infect 2021	France, 2013-2018	210	36.7% (77/210)	1-year mortality 38.2% (73/191)
Rieg S et al, Clin Infect Dis 2014	Germany, 2006-2012	203	24.6% (50/203) within the first 60 days	1-year mortality - 39.5% (19/43) in surgical patients - 54.3% (70/129) in patients without early surgery
Jean B et al, JAMA Netw Open 2024	France, 2016-2022	216	28.7% (62/216) within the first 15 days	30-day mortality 20.8% (45/216)
Calderón-Parra J et al, J Infect 2024	Spain, 2008-2022	420	39.5% (166/420)	1-year mortality 39.8% (167/420)
Nielsen RT et al, Heart 2025	Denmark, 2016-2021	918	17.4% (160/918)	- In-hospital mortality 17.1% in surgical patients vs. 27.9% in patients without early surgery

Tattevin P et al Heart 2025 (in press)

JAMA Network Open

Original Investigation | Infectious Diseases

β-Lactam Inoculum Effect in Methicillin-Susceptible *Staphylococcus aureus* Infective Endocarditis

Baptiste Jean, MD; Maelys Crolle, PharmD; Candice Pollani, PharmD; Adèle Le Guilloux; Guillaume Martin-Blondel, PhD; Pierre Tattevin, PhD; Audrey Le Bot, MD; David Luque Paz, MD; François Guérin, PhD; Vincent Cattoir, PhD; Laurence Armand-Lefevre, PhD; Signara Gueye; François-Xavier Lescure, PhD; Xavier Duval, PhD; Clémence Massip, PhD; Pierre Delobel, PhD

Figure 3. One-Month Survival Curves in Methicillin-Susceptible Staphylococcus aureus Left-Sided Infective Endocarditis





Jean B et al JAMA Network Open 2024

Si c'était une EI sur prothèse valvulaire, quel(s) traitement(s) ?

1. céfazoline
2. céfazoline + gentamicine
3. céfazoline + gentamicine + rifampicine
4. céfazoline + gentamicine *puis* rifampicine
5. céfazoline + rifampicine

Si c'était une EI sur prothèse valvulaire, quel(s) traitement(s) ?

1. céfazoline
2. céfazoline + gentamicine
3. céfazoline + gentamicine + rifampicine
4. **céfazoline + gentamicine *puis* rifampicine**
5. céfazoline + rifampicine

Treatment of methicillin-susceptible staphylococcal prosthetic valve endocarditis



[1]6 weeks after the first day of effective therapy: negative blood culture in the case of initial positive blood culture or day of surgery if valve cultures are positive.
[2]The choice of cefazolin *vs* (cl)oxacillin should follow the same rules than for NVE

Treatment of methicillin-resistant staphylococcal prosthetic valve endocarditis (or in case of allergy to betalactams)



[1]6 weeks after the first day of effective therapy: negative blood culture in the case of initial positive blood culture or day of surgery if valve cultures are positive.

Strady C et al. Infect Dis Now 2025

Dapto plutôt que vanco en 1ère ligne pour les EI à SARM ou SCNMR

1. **Efficacités équivalentes si bien utilisées**
2. **Daptomycine + simple et mieux tolérée**
   - ✓ Dosages ‘optionnels’
   - ✓ Pas besoin de dose de charge
   - ✓ Surveillance bio 1/semaine (CPK, éosino)
3. Sans négliger les contraintes de la daptomycine
   - ✓ **Fortes doses (10 mg/kg x 1/j)**
   - ✓ Stop statines
   - ✓ **Association tant que patient bactériémique**
     (+ betalactamine ou fosfomycine)

Delgado V et al. Eur Heart J 2023 *Strady C et al. Infect Dis Now 2025*

Mémo: antibiothérapie des endocardites à staphylocoques

- Pas d'aminoside dans les **EI sur valve native** (sauf choc?)
- **Bithérapie si EI sur prothèse**: dapto ou céfazoline

  \+ *gentamicine **puis** rifampicine*
- Pour les SAMS, une **bêtalactamine antistaphylococcique**: (cl)oxacilline ou **céfazoline**
- **Dapto pour les staphylocoques meti-R,** en association jusqu'à hémoc neg

Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study

Mia Marie Pries-Heje [1]*, Julie Glud Hjulmand[1], Ingrid Try Lenz[1], Rasmus Bo Hasselbalch [2,3], Jonas Agerlund Povlsen[4], Nikolaj Ihlemann[5,6], Nana Køber[6], Marlene Lyngborg Tofterup[5], Lauge Østergaard [1], Morten Dalsgaard[3], Daniel Faurholt-Jepsen[7], Malene Wienberg[8], Ulrik Christiansen[9], Niels Eske Bruun [10,11,12], Emil Fosbøl[1], Claus Moser[13,14], Kasper Karmark Iversen [2,3,12†], and Henning Bundgaard [1,12†]



Pries-Heje MM et al. Eur Heart J 2023

Clinical implementation of partial oral treatment in infective endocarditis: the Danish POETry study



Pries-Heje MM et al. Eur Heart J 2023



Delgado V et al. Eur Heart J 2023

A systematic review of dalbavancin efficacy as a sequential therapy for infective endocarditis

Gabriele Maria Leanza[1] · Emanuele Rando[1] · Federico Frondizi[1] · Eleonora Taddei[2] · Francesca Giovannenze[2] · Juan P. Horcajada[3] · Giancarlo Scoppettuolo[2] · Carlo Torti[1,2]

- ✓ **263 EI traitées par dalbavancine en 'consolidation'**
  - **128 valves natives / 107 prothèses** / 28 dispositifs intra-cardiaques
  - **83 SCN / 78 *S. aureus* (19 SARM) / 53 entérocoques** / 35 streptos
- ✓ **Echecs <10%, semblent plus fréquents si**
  - Relais précoce par dalbavancine (<2 semaines IV)
  - EI à entérocoques (*E. faecalis*)
- ✓ **Tolérance excellente**

Leanza GM et al. Infection 2024

Messages – diagnostic

1. Trouvez un moyen pour que les flacons d'hémocultures soient bien remplis chez vous
2. Suspicion d'EI =>
   - 3 paires d'hémocultures bien remplies sur ponction unique
   - autres prélèvements guidés par clinique
3. Si pas de diagnostic à 48-72 h
   - Tel labo pour prolongation incubation hémocultures
   - Sérologies *Bartonella* sp. et fièvre Q
   - Chercher autre chose…
   - Prélèvement pour métagénomique ?

Messages – traitement empirique

1. SAMS = ennemi public n° 1
   - Il faut que le schéma comprenne (cl)oxa ou céfazo

2. Couverture des 2 autres ‘usual suspects’
   - amoxicilline pour les streptocoques
   - bactéricide sur *E. faecalis* si combiné à céfazoline

Amoxicilline (200 mg/kg/j) + céfazoline (100 mg/kg/j)

Messages: antibiothérapie des endocardites à staphylocoques

- Pas d'aminoside dans les **EI sur valve native** (sauf choc?)
- **Bithérapie si EI sur prothèse**: dapto ou céfazoline

  \+ *gentamicine **puis** rifampicine*
- Pour les SAMS, une **bêtalactamine antistaphylococcique**: (cl)oxacilline ou **céfazoline**
- **Dapto pour les staphylocoques meti-R,** en association jusqu'à hémoc neg

18th International Symposium

on Modern Concepts in Endocarditis
and Cardiovascular Infections

RENNES, FRANCE

JUNE 28-30, 2026

Tous les 2 ans, 100% anglophone, alternance Europe / reste du Monde

- Endocardites & autres infections cardio-vasculaires
- Infectiologues/Cardiologues/microbios/chir cardiaque/imagerie
- Objectifs 2026: 250/300 participants
- Sessions plénières + posters

https://www.iscvid.org/